Selah Genomics Buys EnGenCore | GenomeWeb

NEW YORK (GenomeWeb News) – Newly formed Selah Genomics today announced that it has acquired EnGenCore for an undisclosed amount.

Selah CEO Michael Bolick said in a statement that the purchase of EnGenCore will lead to the development of "molecular and genomic technology at [the University of South Carolina] with an eye toward helping translate this impactful technology to the clinic." The firm's Clinical Genomics Center is located at the GHS Institute for Translational Oncology Research in close proximity to the USC medical school, he noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.